AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has launched the UmbREALung study, a prospective, observational, real-world multi-cohort study focusing on patients with non-small cell lung cancer (NSCLC) who are starting treatment with approved drugs developed by AstraZeneca or through its alliances. The study aims to evaluate the effectiveness of these treatments across different stages of NSCLC, including resectable, unresectable, and metastatic cases. This research is significant as it seeks to provide real-world insights into the performance of these drugs, potentially influencing treatment protocols and patient outcomes.
The study tests approved drugs developed by AstraZeneca or in alliance, used either as monotherapy or in combination, to treat NSCLC at various stages. The goal is to assess the real-world application and effectiveness of these treatments.
The UmbREALung study is observational and ambispective, meaning it includes both retrospective and prospective data collection. It is structured into three cohorts based on NSCLC stages, with treatment decisions made independently by physicians. The primary purpose is to gather real-world data on drug effectiveness.
The study began on December 16, 2024, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 7, 2025. These dates are crucial as they mark the progress and updates in the study’s findings.
This study could impact AstraZeneca’s stock performance positively by providing evidence of their drugs’ effectiveness, potentially boosting investor confidence. As the study progresses, it could also influence the competitive landscape in the NSCLC treatment market, where AstraZeneca faces significant competition.
The UmbREALung study is ongoing, with further details available on the ClinicalTrials portal.